A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
50–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of Mild to Moderate Alzheimer's disease (MMSE 16-26)
6 Month cognitive decline
Stable marketed AD therapy x2 months or additional marketed AD therapy during study
Score of \<=4 on the Modified Hachinski Ischemia Scale
CT results consistent with Alzheimer's disease
Medically stable
6 years education
Reliable study partner (caregiver)
Must be able to swallow capsules
You may not be if
Premenopausal women
Dementia due to other causes than Alzheimer's disease
History of stroke
Immunocompromised
Active peptic ulcer, GI bleed, chronic inflammatory bowel disease, chronic diarrhea or past GI surgery that would impact drug absorption
Unstable Vitamin B-12 deficiency
Hematologic or solid malignancy within 5 years
Geriatric Depression Scale \>= 6
Unstable medical condition
Alcohol or drug abuse history with 12-months of study entry
Significant drug allergy
Alzheimer's disease modification experimental therapy with 12 months of study entry
Prisoners, compulsory psychiatric patients, or residents of nursing home or skilled nursing facility at entry
Any other experimental therapy with 30-days of study entry
Clareo Health | A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
